Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma

被引:27
|
作者
Tsuda, Y. [1 ]
Tsoi, K. [1 ]
Parry, M. C. [1 ]
Stevenson, J. D. [1 ]
Fujiwara, T. [1 ]
Sumathi, V [1 ]
Jeys, L. M. [1 ]
机构
[1] Royal Orthopaed Hosp, Dept Oncol, Birmingham, W Midlands, England
来源
BONE & JOINT JOURNAL | 2020年 / 102B卷 / 06期
关键词
HIGH-DOSE METHOTREXATE; NONMETASTATIC OSTEOSARCOMA; NEOADJUVANT CHEMOTHERAPY; HISTOLOGIC RESPONSE; OSTEOGENIC-SARCOMA; PROGNOSTIC-FACTORS; DELAYED SURGERY; EXTREMITIES; EURAMOS-1; CISPLATIN;
D O I
10.1302/0301-620X.102B6.BJJ-2019-1307.R1
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Aims To assess the correlation between the histological response to preoperative chemotherapy and event-free survival (EFS) or overall survival (OS) in patients with high-grade localized osteosarcoma. Methods Out of 625 patients aged <= 40 years treated for primary high-grade osteosarcoma between 1997 and 2016, 232 patients without clinically detectable metastases at the time of diagnosis and treated with preoperative high-dose methotrexate, adriamycin and cisplatin (MAP) chemotherapy and surgery were included. Associations of chemotherapy-induced necrosis in the resected specimen and EFS or OS were assessed using Cox model and the Pearson's correlation coefficients (r). Time-dependent receiver operating characteristic analysis was applied to determine the optimal cut-off value of chemotherapy-induced necrosis for EFS and OS. Results OS was 74% (95% confidence interval (CI) 67 to 79) at five years. Median chemotherapy- induced necrosis was 85% (interquartile range (KIR) 50% to 97%). In multivariate Cox model, chemotherapy-induced necrosis was significantly associated with EFS and OS (hazard ratio (HR) = 0.99 (95% CI 0.98 to 0.99); p < 0.001 and HR = 0.98 (95% CI 0.97 to 0.99); p < 0.001, respectively). Positive correlation was observed between chemotherapy-induced necrosis and five-year EFS and five-year OS (r = 0.91; p < 0.001, and r = 0.85; p < 0.001, respectively). The optimal cut-off value of chemotherapy-induced necrosis for five-year EFS and five-year OS was 85% and 72%, respectively. Conclusion Chemotherapy-induced necrosis in the resected specimen showed positive correlation with EFS and OS in patients with high-grade localized osteosarcoma after MAP chemotherapy. In our analysis, optimal cut-off values of MAP chemotherapy-induced necrosis in EFS and OS were lower than the commonly used 90%, suggesting the need for re-evaluation of the optimal cut-off value through larger, international collaborative research.
引用
收藏
页码:795 / 803
页数:9
相关论文
共 50 条
  • [1] The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma
    Eilber, FC
    Eilber, FR
    Eckardt, J
    Rosen, G
    Riedel, E
    Maki, RG
    Brennan, MF
    Singer, S
    ANNALS OF SURGERY, 2004, 240 (04) : 686 - 695
  • [2] The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma - Discussions
    Pollock, RE
    Eilber, FC
    Wanebo, HJ
    Goodnight, JE
    Meakins, JL
    ANNALS OF SURGERY, 2004, 240 (04) : 695 - 697
  • [3] The Effect of Pre-irradiation Chemotherapy on Event-free and Overall Survival in Pediatric Low-grade Glioma
    Murphy, E. S.
    Merchant, T. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S117 - S117
  • [4] A Novel Tool to Predict the Overall Survival of High-Grade Osteosarcoma Patients after Neoadjuvant Chemotherapy: A Large Population-Based Cohort Study
    Huang, Zhangheng
    Wang, Yu
    Wu, Ye
    Guo, Chuan
    Li, Weilong
    Kong, Qingquan
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [5] RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy
    Ball, Brian J.
    Hsu, Meier
    Devlin, Sean M.
    Famulare, Christopher
    Cai, Sheng F.
    Dunbar, Andrew
    Epstein-Peterson, Zachary D.
    Menghrajani, Kamal
    Glass, Jacob L.
    Taylor, Justin
    Viny, Aaron D.
    Goldberg, Aaron D.
    Tallman, Martin S.
    Stein, Eytan M.
    BLOOD, 2019, 134
  • [6] Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinoma
    Robin Schmitz
    Rui Mao
    Dimitrios Moris
    John H. Strickler
    Dan G. Blazer
    Annals of Surgical Oncology, 2021, 28 : 114 - 120
  • [7] Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinoma
    Schmitz, Robin
    Mao, Rui
    Moris, Dimitrios
    Strickler, John H.
    Blazer, Dan, III
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (01) : 114 - 120
  • [8] Overall Survival after Systemic Chemotherapy in Patients with High-Grade Appendiceal Cancer Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
    Bharath Nagarajan
    Jaiveer Singh
    Ashita Gelli
    Jayarani Lenin
    Selva Prabhu
    Sudharsanan Sundaramurthi
    Journal of Gastrointestinal Surgery, 2022, 26 : 2628 - 2629
  • [9] Overall Survival after Systemic Chemotherapy in Patients with High-Grade Appendiceal Cancer Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
    Nagarajan, Bharath
    Singh, Jaiveer
    Gelli, Ashita
    Lenin, Jayarani
    Prabhu, Selva
    Sundaramurthi, Sudharsanan
    JOURNAL OF GASTROINTESTINAL SURGERY, 2022, 26 (12) : 2628 - 2629
  • [10] Chemotherapy and Survival in Patients with Primary High-Grade Extremity and Trunk Soft Tissue Sarcoma
    Graham, Danielle S.
    van Dams, Ritchell
    Jackson, Nicholas J.
    Onyshchenko, Mykola
    Eckardt, Mark A.
    DiPardo, Benjamin J.
    Nelson, Scott D.
    Chmielowski, Bartosz
    Shabason, Jacob E.
    Singh, Arun S.
    Eilber, Fritz C.
    Kalbasi, Anusha
    CANCERS, 2020, 12 (09) : 1 - 13